Sirgartan Therapeutics
Anthony Hall is an accomplished medical professional with extensive experience in leadership roles within the pharmaceutical and biotechnology sectors. Currently serving as the Chief Medical Officer at Sirgartan Therapeutics and Healx, Anthony also co-founded and holds a position on the Board of Trustees and as a Scientific Advisor for Beacon for Rare Diseases. Additionally, Anthony is a member of the Real World Data Working Group at the Faculty of Pharmaceutical Medicine and serves on the Scientific Advisory Board of Duchenne UK. Anthony Hall earned an MB BS in Medicine from the Royal Free Hospital School of Medicine (1986-1991) and a BSc AKC in Physiology & Pharmacology from King's College London (1983-1986).
This person is not in any teams
This person is not in any offices
Sirgartan Therapeutics
Sirgartan believes that mental illness should no longer be underestimated and stigmatised. Sirgartan Therapeutics is a clinical-stage drug development company established with the vision to transform the treatment paradigm for OCD (obsessive compulsive disorder) and deliver life-changing medicines for patients with this condition, many of whom are poorly treated with current therapies. The company is working with the University of Cambridge, UK on a first-in-class treatment based on modulation of glutamate. Investment obtained through initial seed-funding has enabled advanced pre-clinical studies to be carried out by the University of Cambridge. These studies have shown very encouraging results, much to the satisfaction of Professor Trevor Robbins, Chief Scientific Advisor to Sirgartan, and to the submission of a patent application for the identified therapy and its method of action. The organisation is now seeking further funding to enable progression into clinical studies. Please contact us should you or your organisation have an interest in joining us on the journey.